Clinical Trials

Clinical trials involve the administration of an investigational new drug to human subjects under the supervision of qualified investigators in accordance with good clinical practice (GCP) requirements and after clearance by the Food and Drug Administration (FDA) of an investigational new drug (IND) application.  

Further, an independent review board (IRB) for each institution participating in the clinical trial must review and approve the plan for any clinical trial, its informed consent form, and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans.

Acrivon Therapeutics is currently recruiting patients in the United States for the following active clinical trials. Please follow the links below for more information for each study and site location.

Clinical Trial
Details and Link for More Information

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Protocol ID: NCT05548296

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon’s OncoSignature® test status.

For more information please visit: https://clinicaltrials.gov/study/NCT05548296

ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects With Advanced Solid Tumors

Protocol ID: NCT06667141

The Phase 1 monotherapy clinical trial for ACR-2316 is designed to assess the safety and tolerability of ACR-2316. Additional objectives include the determination of the maximal tolerated dose and recommended Phase 2 monotherapy dose, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity.

For more information please visit: https://clinicaltrials.gov/study/NCT06667141